Evidence map›Paper›PMID 40894838›Full record

ArticleCJC open2025

Device Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit?

Robert Wannamaker, Roopinder K Sandhu, Justin A Ezekowitz, Sheri L Koshman, Derek S Chew, Luke R Gagnon, Chen-Hsiang Ma, Chandu Sadasivan, Gavin Y Oudit, Finlay A McAlister

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Robert WannamakerDivision of General Internal Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Roopinder K SandhuDivision of Cardiology, Cumming Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Justin A EzekowitzMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Sheri L KoshmanMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Derek S ChewDivision of Cardiology, Cumming Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Luke R GagnonMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Chen-Hsiang MaMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Chandu SadasivanMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Gavin Y OuditMazankowski Alberta Heart Institute Heart Function Clinic, University of Alberta, Edmonton, Alberta, Canada.
Finlay A McAlisterDivision of General Internal Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To determine what proportion of device-eligible patients with heart failure treated in a specialized clinic are on optimal guideline-directed medical therapy (GDMT) at the time of device referral and their benefit-risk status. Methods: A cohort study was conducted of all patients seen between January 2013 and August 2024. We characterized GDMT by the modified Heart Function Collaboratory score at the time of device referral and grouped patients by Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-ICD) benefit-risk score. Results: Of 250 patients potentially eligible for a primary prophylaxis implantable cardioverter defibrillator (ICD), 136 (54.4%) were referred within 6 months of GDMT initiation-34 (25%) were in the lowest MADIT-ICD benefit-risk group and 6 (9.7%) of those not referred were in the highest benefit-risk group. No differences occurred in ICD referral based on sex ( Conclusions: Within 6 months of initiating GDMT, more than half of eligible patients with heart failure had been referred for a device, but one quarter were in the group least likely to benefit from a device, and not all were on optimal GDMT.

Identifiers

PMID40894838
PMCPMC12399137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.